Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis

Arthritis Rheum. 1999 Mar;42(3):443-7. doi: 10.1002/1529-0131(199904)42:3<443::AID-ANR8>3.0.CO;2-Q.

Abstract

Objective: To determine serum lipoprotein(a) (Lp[a]) concentrations and to analyze the apolipoprotein(a) (Apo[a]) phenotype in patients with rheumatoid arthritis (RA).

Methods: The subjects included 131 patients with RA and 200 healthy control subjects. Serum Lp(a) concentrations were measured by enzyme-linked immunosorbent assay, and the Apo(a) phenotype was determined by immunoblotting. HLA-DR typing was also done.

Results: The mean serum Lp(a) level was significantly higher (P < 0.001) in the RA patients (27.5 mg/dl) than in the controls (15.0 mg/dl). The S3 allele was found in 70.0% of the patients versus 39.5% of the controls (P < 0.001). There was no significant difference in HLA-DR4 positivity between patients with and without the S3 phenotype.

Conclusion: The serum Lp(a) level was increased in patients with RA, possibly partly because of S3 phenotype predominance.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents / administration & dosage
  • Apolipoproteins A / blood*
  • Apolipoproteins A / genetics
  • Arteriosclerosis / complications
  • Arteriosclerosis / drug therapy
  • Arteriosclerosis / genetics*
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Arthritis, Rheumatoid / genetics*
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Female
  • HLA-DR Antigens / blood
  • HLA-DR Antigens / genetics
  • Humans
  • Lipoprotein(a) / blood*
  • Lipoprotein(a) / genetics
  • Male
  • Middle Aged
  • Phenotype
  • Prednisolone / administration & dosage

Substances

  • Anti-Inflammatory Agents
  • Apolipoproteins A
  • Cholesterol, HDL
  • Cholesterol, LDL
  • HLA-DR Antigens
  • Lipoprotein(a)
  • Prednisolone